DIVISLAB

** Shares of Divi's Laboratories DIVI.NS rise 3% to 6,561 rupees, its biggest jump in three months

** Brokerage Citi says 2026 can be an inflection year for DIVI, calls it their 'top' pharma pick in India

** Adds co has strong pipeline catalysts over the next 12 months; generic segment expected to witness a recovery

** Expcts co's revenue to expand by 3 times and EBITDA to rise 4 times over FY25-FY30e

** Citi has a "buy" rating on co with PT at 9,140 rupees

** DIVI rated "hold" on avg by 27 analysts covering it; median PT at 6780 rupees - data compiled by LSEG

** In 2025, DIVI gained ~5%

(Reporting by Komal Salecha)

(([email protected];))

Nov 7 (Reuters) - Divi's Laboratories Ltd DIVI.NS:

• SEPT-QUARTER CONSOL NET PROFIT 6.89 BILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 27.15 BILLION RUPEES

Source text: ID:nBSE1tbLVZ

Further company coverage: DIVI.NS

(([email protected];;))

Aug 6 (Reuters) - India's Divi's Laboratories DIVI.NS reported first-quarter profit below estimates on Wednesday, as manufacturers producing generic drugs continued to be negatively impacted by pricing pressures in the key U.S. market, sending shares down 3.3%.

The Hyderabad-based company's consolidated net profit rose 26.7% to 5.45 billion rupees ($62 million) for the quarter ended June 30.

Analysts, on average, had expected 5.75 billion rupees, as per data compiled by LSEG.

Indian generic drugmakers, which get a significant chunk of their revenue from the U.S., have been grappling with weak pricing amid stiff competition in the region.

Divi's, one of India's largest manufacturers of active pharmaceutical ingredients (API), has flagged pricing pressure and high competition in its generics business in global markets, adding that it aims to increase its market share by launching molecules as they get off patent.

APIs are key chemical components in a drug that produce the intended therapeutic effects. Divi's exports to more than 100 countries, with the U.S. and Europe being its core markets

The company's shares were down 2.5% before the news, in tandem with the rest of the pharma stocks on U.S. President Donald Trump's potential tariff threat.

The drugmaker's peers Cipla CIPL.NS and Dr Reddy's REDY.NS also reported subdued June-quarter sales in the U.S.

Revenue from operations for Divi's rose 14% to 24.10 billion rupees, also missing analysts' estimates of 24.56 billion rupees.

The company is banking on demand from diabetes and weight-loss drugs manufacturers such as Eli Lilly LLY.N, who cater to skyrocketing customer demand for the drug in global markets.

($1 = 87.7050 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Janane Venkatraman)

(([email protected]; 8800437922;))

** Divi's Laboratories DIVI.NS shares climb 2% to 7,030 rupees

** Top gainer on pharma index .NIPHARM, which is trading 0.4% lower

** HSBC Global Research upgrades stock to "buy" from "reduce"

** HSBC lifts PT to 7,900 rupee from 5,020 rupees, highest on the Street among 24 analysts, per data complied by LSEG

** Notes "long runway of growth" for DIVI led by strong demand for weight-loss drug tirzeptide, the active ingredient in Eli Lilly's LLY.N Mounjaro

** Expects revenue potential of $450 mln for DIVI from peptides such as GLP-1s by 2030

** Avg rating on DIVI is "hold"; median PT 6,460 rupees - data compiled by LSEG

** DIVI best YTD performer on 20-member pharma index with 15% climb

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** India's Divi's Laboratories DIVI.NS gains 3.6% to 6,698 rupees

** Stock top pct gainer on pharma index .NIPHARM, which is trading 0.7% higher

** India's top API maker by capacity says it signed a long-term supply agreement with a global pharma company for supply of advanced intermediates, without naming the co

** Cost of capacity addition under deal expected to be between 6.50 bln rupees and 7.50 bln rupees ($76 mln and $88 mln) - DIVI

** DIVI says it expects "meaningful" revenue contribution from the deal

** Morgan Stanley analysts estimate "incremental revenue" of 16.90 bln rupees to 18.90 bln rupees after the deal

** DIVI top pct gainer on pharma index YTD, climbing 9.9%, vs NIPHARM's 8% decline

($1 = 85.0550 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** Shares of India's Divi's Laboratories DIVI.NS rise 2.7% to 6444 rupees

** Drugmaker's Q4 consol PAT rose 23% y/y to 6.62 billion rupees ($77.3 million), total income rose 12%

** YTD stock up ~6%

($1 = 85.6040 Indian rupees)

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

** India's Divi's Laboratories DIVI.NS gains 5% to 6,228.50 rupees

** DIVI's proposed 18MT capacity and a fully integrated infrastructure for tirzeptide, the active ingredient for Lilly's blockbuster Mounjaro, will give DIVI a competitive edge over rivals, says Citi

** Brokerage hikes PT on active ingredients maker to 7,050 rupees from 6,850 rupees

** U.S. drugmaker Eli Lilly's LLY.N oral weight-loss drug orforglipron is the next addition to DIVI's pipeline, which is a "big one", says Citi

** Drugmaker has so far announced a capex of $170 mln, which CITI believes is primarily for GLP-1 class of weight-loss drugs

** DIVI second-biggest gainer on Nifty pharma index NIPHARM which is up 1.2%.

** Brokerage calls DIVI its "top pharma pick" and forecasts over $800 mln revenue by 2030 from GLP-1s

** Avg rating of 21 analysts on DIVI at "hold"; median PT is 5,737.50 rupees - data compiled by LSEG

** DIVI up 2% YTD vs pharma index's 6% decline

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** Shares of Divi's Laboratories DIVI.NS jumps 3.8% to 5851 rupees, their biggest one-day gain since February 3

** DIVI biggest pct gainer on Nifty pharma index, which is up 0.05%

** Co signs deal with a global pharma co to manufacture, supply advanced intermediates

** Co also plans 6.5 billion rupees - 7 billion rupees ($76.4 million-$82.2 million) worth of capacity addition at its manufacturing facilities

** Avg rating on stock is "hold;" median PT is 5737.5 rupees - data compiled by LSEG

** Stock down 3.7% YTD vs 9.7% fall in pharma index

($1 = 85.1130 Indian rupees)

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

** Divi's Laboratories DIVI.NS rises ~5% in second session of gains post Q3 results

** Co's custom synthesis segment grows 45% y/y in Q3

** BOB Capital upgrades to "hold" from "sell", citing co's effective opportunity utilisation in the fast growing segment

** Jefferies retains "hold" despite custom synthesis improving product mix and profit

** Says co needs to overcome high rev concentration of key heart failure drug the patent for which will expire in 2026

** Co working on glucose stabilising hormone GLP-1 manufacturing process to diversify

** Systematix Equities says DIVI seeing interest in GLPs from several MNCs; has strong position due to backward integration

** But retains "sell" on rich stock valuation

** DIVI rated "hold" on avg; mean PT of 5,427 rupees is 12.2% downside to current price of 6,185.7 rupees

** Stock up 66% YTD

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

HYDERABAD, Feb 3 (Reuters) - India's Divi's Laboratories DIVI.NS reported a better-than-expected quarterly profit on Monday, aided by strong performance of its business that focuses on customised production of chemical compounds used in drugs, sending its shares higher.

The company's consolidated net profit jumped 64.5% to 5.89 billion rupees ($67.6 million) in the third quarter, slightly above analysts' estimates of 5.13 billion rupees, as per LSEG data.

The Hyderabad-based drugmaker's shares reversed course from a 0.2% dip to trade 3.3% higher after the results.

Divi's is one of India's largest manufacturers of active pharmaceutical ingredients (API), key components of a drug that produce the intended therapeutic effects. Its client list spans more than 100 countries and includes major drugmakers such as Novartis NOVN.S.

Its revenue from operations climbed 25% to 23.19 billion rupees during the quarter, roughly in line with analysts' estimate of 23.43 billion rupees.

The company also provides contract development and manufacturing (CDMO) services. Divi's and its local peers stand to gain as major drugmakers are diversifying their supply chain to limit their reliance on China.

Divi's, in particular, has said it is also banking on demand from obesity drug manufacturers as they scramble to meet skyrocketing customer demand.

However, its generics business, much like those of its peers, is facing pricing pressure, a situation it hopes will stabilise this year.

($1 = 87.1190 Indian rupees)

(Reporting by Rishika Sadam and Kashish Tandon; Editing by Rashmi Aich and Savio D'Souza)

(([email protected];))

Jan 2 (Reuters) - Divi's Laboratories Ltd DIVI.NS:

• DIVI'S LABORATORIES - STARTS COMMERCIAL OPERATIONS AT UNIT III IN ANDHRA PRADESH

Source text: ID:nBSE2pGbB7

Further company coverage: DIVI.NS

(([email protected];))

Adds details paragraph 2 onwards

Dec 31 (Reuters) - Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public offering, draft papers showed on Tuesday, at the fag end of what has been a red-hot year for companies listing on the stock market.

Anthem, whose services include early-stage drug discovery and drug efficacy testing, said private equity firm True North and drugmaker DavosPharma are among investors who will sell shares in the IPO.

The company will not sell any shares and it did not give any other details on the offering.

The Indian IPO market has been bustling this year, with over 300 companies having raised $17.5 billion as of mid-December, more than double the amount raised last year, LSEG data showed.

That gives it the top spot globally in terms of proceeds and volumes, according to consultancy firm KPMG.

Anthem, which began operations in 2007 and has two manufacturing facilities, is also going public at a time when global drugmakers are turning to India and other markets to limit their reliance on Chinese contractors.

Begaluru-based Anthem also makes active pharmaceutical ingredients (API), which are the main component of a drug, as well as dietary supplements and probiotics.

It competes with the likes of Syngene International SYNN.NS, Divi's Laboratories DIVI.NS and newly-listed Sai Life Sciences SAIE.NS among Indian API makers.

($1 = 85.5720 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza)

(([email protected]; 8800437922;))

** Shares of Divi's Laboratories DIVI.NS settle down 2.6% 6,096.20 rupees, their worst day since mid-August

** DIVI second-biggest pct loser among pharma stocks .NIPHARM which is up 0.2%

** Novartis NOVN.S failed to persuade U.S. court on Wednesday to halt generic version of its blockbuster heart drug Entresto

** Divi's Labs supplies active pharmaceutical ingredients for Entresto

** Stock had dropped 4% in mid-August when Novartis lost initial bid to block generic version of Entresto

** DIVI among 11 stocks on 20-member pharma index rated "hold", rest rated "buy" or higher - LSEG data

** Stock up ~56% YTD vs pharma index's 34% gain

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

** Divi's Laboratories DIVI.NS shares up 3.8%, top gainer in Nifty pharma index .NIPHARM which is up 2.6%

** Citi says DIVI remains its top pick in Indian pharmaceutical sector

** Brokerage expects DIVI's key drug Entresto active pharma ingredient (API) sales to rise vs street expectations of decline

** DIVI likely to supply Entresto API to generics manufacturers as well after patent expires - Citi

** DIVI snaps three-day losing streak

** Citi has "buy" rating on stock, with PT at 6,850 rupees

** Analysts on average rate stock a "hold", with median PT at 5,285 rupees, per LSEG data

** DIVI up ~ 59% YTD vs ~32% gains in pharma index

(Reporting by Sethuraman NR)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

** Shares of Divi's Laboratories Ltd DIVI.NS up 4.8% at 5,811.70 rupees

** DIVI rose as much as 6% to record 5,878 rupees earlier in session

** Citi begins coverage of drugmaker with "buy" and Street-high PT of 6,400 rupees as it sees DIVI benefiting from supply-chain diversification of active pharmaceutical ingredients for GLP-1s or weight loss drugs

** DIVI has potential to become prominent supplier to Eli Lilly LLY.N as it diversifies suppliers with U.S. Biosecure Act looming and given DIVI's own capabilities in scaling up at industrial scale - Citi

** Analysts tracking DIVI rate it "hold" on avg, same as 10 other stocks on 20-member Nifty Pharma .NIPHARM index - LSEG data

** DIVI top pct gainer on NIPHARM

** Stock's ~48% YTD rise outperforms index's 40% rise

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

** Shares of Divi's Laboratories DIVI.NS gain ~4% at 4,895 rupees

** DIVI top pct gainer on Nifty 50 .NSEI and Nifty pharma index .NIPHARM

** U.S. appeals court puts stay order on US FDA's approval for generic version of Novartis' NOVN.S top-selling heart failure drug Entresto, for which DIVI makes the API Sacubitril, Bloomberg Law reports

** Novartis did not immediately respond to Reuters' request for comment

** "While litigation is still ongoing, the stay on approval blocks the launch of generic version of Entresto for now, which is a positive for DIVI," said Shrikant Akolkar of Nuvama Institutional Equities

** DIVI fell the most in nearly 16 months on Aug. 14 when Novartis lost initial bid to block generic versions of Entresto

** Stock up ~26% YTD vs ~34% gains in pharma index

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** Shares of Divi's Laboratories DIVI.NS fall 4.2% to 4,656 rupees, the most on the Nifty 50 .NSEI

** Novartis NOVN.S loses initial bid to block generic versions of its top-selling heart drug Entresto, for which Divi's supplies pharma ingredients, or APIs

** Entresto is among largest drugs in Divi's portfolio and generics could hurt FY27 EPS by 10%, says Kotak Institutional Equities

** Adds: "We have not factored in a generic entry in Entresto, which will hurt earnings, while valuations continue to stay prohibitively expensive"

** Brokerage reiterates "sell" and a target price of 3,600 rupees, an implied downside of about 26%

** Analysts avg rating on DIVI is "hold"; median target price is 4,437.50 rupees apiece --LSEG data

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

** Shares of Divi's Laboratories DIVI.NS fall 1.7% to 4,893 rupees

** Stock among top losers on Nifty 50 index .NSEI, which is down 1.81%

** DIVI saw a 21% rise in Q1 consolidated net profit, however analysts flag slow margin recovery

** Co's generic API business reported a muted growth of ~1% Y/Y, with the increase in volumes being offset by steep price erosion, said analysts at Antique Stock Broking

** Continued pricing pressure in generic-APIs, overheads at Kakinada plant and custom-synthesis project would drag margins- Ambit Capital Research

** Twenty-two analysts covering the stock on avg have a "hold" rating; median PT is 3,965 rupees - LSEG data

** Stock up 7% so far this qtr, vs a 10.6% rise in Nifty pharma index .NIPHARM

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

July 19 (Reuters) - Divi's Laboratories Ltd DIVI.NS:

• DIVI'S LABS - US-FDA INSPECTION OF COMPANY'S UNIT-II MANUFACTURING FACILITY AT ANDHRA PRADESH

• DIVI'S LABS - US-FDA INSPECTION IS SUCCESSFULLY COMPLETED WITH ONE PROCEDURAL OBSERVATION

Source text for Eikon: [ID:]

Further company coverage: DIVI.NS

(([email protected];))

June 21 (Reuters) - Divi's Laboratories Ltd DIVI.NS:

• NSE CIRCULAR: DIVI'S LABORATORIES AND TRENT LTD NOT AVAILABLE FOR TRADING IN T+0 ROLLING SETTLEMENT CYCLE ON JUNE 24

Source text for Eikon: [ID:]

Further company coverage: DIVI.NS

(([email protected];;))

** Shares of Divi's Laboratories DIVI.NS rise 5.7% to two-year high of 4,359 rupees, rallying for 6th session in a row

** DIVI's top gainer on benchmark Nifty 50 .NSEI and pharma index .NIPHARM

** Co's Q4 consol net profit rose ~68% Y/Y on strong demand

** Motilal Oswal expects DIVI to gain market share and maintain profitability in active pharmaceutical ingredients (API) portfolio

** Prabhudas Lilladher says gross margins stabilized, likely to improve on better product mix and stable raw material prices

** Trading vol is over 4x the 30-day avg, busiest day in a year

** DIVI up 10% YTD, more than the Nifty 50 (~6%), but less than pharma index (~14%)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

April 25 (Reuters) - Divi's Laboratories Ltd DIVI.NS:

• IN PROCESS OF ENTERING INTO A LONG-TERM SUPPLY AGREEMENT WITH A CUSTOMER

• PLANNING FOR CAPACITY ADDITION AT ITS MANUFACTURING FACILITY

• ESTIMATED INVESTMENT BETWEEN 6.50 BLN RUPEES TO 7 BLN RUPEES

• PROPOSED FACILITY IS ADDED EXPECTED TO BE OPERATIONAL AROUND JAN, 2027

• PLANNING FOR CAPACITY ADDITION AT ITS MANUFACTURING FACILITY WITH ESTIMATED INVESTMENT BETWEEN 6.5-7 BLN RUPEES

Further company coverage: DIVI.NS

(([email protected];))

** Divi's Laboratories' DIVI.NS has jumped ~9% in past five sessions, set for its best week since May 2023

** Stock last up 0.6% on the day, looking to extend a five-session winning run

** Earlier this week, BofA double-upgraded the stock to "buy"

** Divi's is also the top Nifty 50 .NSEI gainer this week, followed by HDFC Bank HDBK.NS and Shriram Finance SHMF.NS

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

** Divi's Laboratories DIVI.NS up 1.6% at ~3,680 rupees, among top Nifty 50 .NSEI gainers

** BofA Securities double upgrades the drug ingredients maker's stock to "buy" from "underperform" on improving earnings outlook and attractive valuation; raises PT to 4,025 rupees

** Brokerage says Divi's is more compelling due to lower risk to earnings growth than at US-focused generic drug makers, who are susceptible to pricing uncertainties

** Expects Divi's EBITDA margins to rise to 33% by FY26 (vs 35% pre-COVID), after likely bottoming out at 27% in FY24

** Despite the upgrade, analysts' avg rating on Divi's remains "sell", per LSEG data

** Wipro WIPR.NS is the only other Nifty 50 stock with an avg "sell" rating

** DIVI trims YTD losses to ~6%; is among three stocks on 20-member Nifty pharma .NIPHARM in the red this year

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

** Shares of Divi's Laboratories DIVI.NS up 3.7% to 3,788.75 rupees, steepest rise since December

** Pharma co reported ~17% rise in Q3 net profit, rev from ops up ~9%

** Jefferies says it is bullish on the co, but expects factors like improvement in pricing pressures for generics to start unfolding only post FY26; cuts FY25E EPS by 3%

** Retains "hold" with unchanged PT of 3,610 rupees

** Brokerage PhillipCapital also flags ongoing margin pressure in generics due to pricing pressures; cuts FY25 EPS by 14%, keeps rating at "neutral" with unchanged PT of 3,300 rupees

** Adds, co has potential to deliver surprise earnings in upcoming quarters

** On avg, analysts' rating equivalent to "sell", their median PT is 3,150 rupees - ~14% discount to its last close - LSEG

** Co top gainer on Nifty Pharma index .NIPHARM, up 0.9%

** Trading volume is 1.3x 30-day avg

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

Nov 16 (Reuters) - Divi's Laboratories Ltd DIVI.NS:

• RECEIVED ORDER PERTAINING TO RECOVERY OF REFUND OF IGST GRANTED, ALLEGED TO BE CLAIMED ERRONEOUSLY

• CO TO FILE APPEAL AGAINST GST ORDER FOR DEMAND OF 820.4 MILLION RUPEES ALONG WITH APPLICABLE INTEREST AND PENALTY

Source text for Eikon: ID:nBSEjdYdj

Further company coverage: DIVI.NS

(([email protected];))

** Shares of Divi's Laboratories DIVI.NS fall as much as 3% to 3,401.1 rupees, steepest intraday fall since Sept. 28

** The pharmaceutical co reported on Monday its consolidated profit fell 29.4% to 3.48 bln rupees ($41.81 million) and missed analysts' estimate of 4.41 billion rupees, as per LSEG data

** Co's margin dragged by higher expenses despite easing price pressures in U.S. markets

** DIVI trading below its 50-day and 100-day simple moving averages since mid October

** Mean rating of 21 analysts covering the stock is "sell"; median PT is 3,030 rupees - LSEG data

** Stock currently down 1.6% trimming YTD gains to 1.1%

($1 = 83.2425 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

HYDERABAD, Nov 6 (Reuters) - India's Divi's Laboratories DIVI.NS reported a bigger-than-expected fall in quarterly profit on Monday, dragged down by higher expenses at a time when generic drug makers have flagged easing price pressures in key markets such as the United States.

Consolidated profit fell 29.4% to 3.48 billion rupees ($41.83 million) in the second quarter ended Sept. 30, compared with 4.93 billion rupees a year earlier. Analysts had expected a profit of 4.41 billion rupees, according to LSEG data.

Hyderabad-based Divi's Labs is one of the country's largest manufactures of active pharmaceutical ingredients (API), which are crucial chemical compounds in a drug that help produce desired health effects. It also provides contract manufacturing services to global players.

The pharmaceutical company, whose core markets are Europe and the United States, said revenue from operations rose 2.9% to 19.09 billion rupees. Exports to the United States and Europe account for more than 60% of its total revenue.

Total expenses rose 15.6% to 15.26 billion rupees. However, raw material costs fell 13% to 7.11 billion rupees.

Shares of Divi's Labs were trading 1.46% higher after the results, compared with a 0.74% rise in the Nifty pharma index .NIPHARM.

Last week, larger rival Sun Pharmaceuticals SUN.NS reported a bigger-than-expected rise in second-quarter profit, driven by strong sales in its domestic and U.S. formulation businesses.

($1 = 83.2000 Indian rupees)

(Reporting by Rishika Sadam; Editing by Subhranshu Sahu)

(([email protected];))

Sept 26 (Reuters) - Divi's Laboratories Ltd DIVI.NS:

• USFDA DELEGATION VISITS COMPANY'S UNIT I AT CHOUTUPPAL, TELANGANA

Further company coverage: DIVI.NS

(([email protected];))

Divi's Laboratories Ltd DIVI.NS:

• DIVI'S LABORATORIES LTD- MADHUSUDANA RAO DIVI TO RETIRE AS WHOLE-TIME DIRECTOR

Source text for Eikon: ID:nBSE7PDgsX

Further company coverage: DIVI.NS